Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2011

View Archived Issues

Vaxent and PREVENT to collaborate on group A Streptococcus vaccine

Novel agents show promise against raltegravir-resistant HIV

Synageva BioPharma expands ongoing study in LAL deficiency

Enrollment complete in phase II bavituximab trial in hepatitis C

First patient receives SanBio's novel cell therapy for disability due to stroke

NeuroSearch designs confirmatory phase III Huntexil trial and complementary studies

Aegerion gives update on European filing for lomitapide

Eisai's broad-spectrum antifungal agents display preclinical promise

YM BioSciences starts phase II trial of CYT-387 in myelofibrosis

HTI-501 enters phase I/II trial in women with cellulite

Ibalizumab shows promise in phase IIb study

Phase II trial investigates safety/efficacy of AZD-3199 in COPD

CSIR researchers disclose new antimycobacterial agents

Janssen synthesizes novel series of phosphodiesterase 10A inhibitors

New peptides with antibacterial activity presented by Universitat de Barcelona

Ingenium Pharmaceuticals designs new protein kinase inhibitors

Multifunctional fusion protein prevents HIV infection in vivo

Roche's new-generation glucose test strip receives FDA clearance

Ironwood's European partner Almirall submits linaclotide MAA

Health Canada approves single-pill combination drug for hypertension

JDRF and iCo Therapeutics partner to support phase II iCo-007 study

Dosing begins in proof-of-concept PEDigree trial

NanoCarrier and Kowa to enter worldwide agreement for NC-6300

Biodel announces phase I data on experimental insulins

FDA issues PDUFA target action date for Surfaxin NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...